{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T07:51:30Z","timestamp":1768722690823,"version":"3.49.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.hoc.2023.05.006","type":"journal-article","created":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T09:04:51Z","timestamp":1687338291000},"page":"993-1003","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Toxicity Management of Systemic Kidney Cancer Therapies"],"prefix":"10.1016","volume":"37","author":[{"given":"Qian","family":"Qin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ellen","family":"Nein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Flaten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.hoc.2023.05.006_bib1","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1021\/jm301847z","article-title":"Development of inhibitors of the PAS-B domain of the HIF-2alpha transcription factor","volume":"56","author":"Rogers","year":"2013","journal-title":"J\u00a0Med Chem"},{"issue":"4","key":"10.1016\/j.hoc.2023.05.006_bib2","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/nchembio.1185","article-title":"Allosteric inhibition of hypoxia inducible factor-2 with small molecules","volume":"9","author":"Scheuermann","year":"2013","journal-title":"Nat Chem Biol"},{"issue":"18","key":"10.1016\/j.hoc.2023.05.006_bib3","doi-asserted-by":"crossref","first-page":"5491","DOI":"10.1158\/0008-5472.CAN-16-0473","article-title":"A\u00a0small-molecule antagonist of HIF2alpha is efficacious in preclinical models of renal cell carcinoma","volume":"76","author":"Wallace","year":"2016","journal-title":"Cancer Res"},{"issue":"9","key":"10.1016\/j.hoc.2023.05.006_bib4","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1200\/JCO.2017.74.2627","article-title":"Phase I dose-escalation trial of PT2385, a first-in-class hypoxia-inducible factor-2alpha antagonist in patients with previously treated advanced clear cell renal cell carcinoma","volume":"36","author":"Courtney","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"15","key":"10.1016\/j.hoc.2023.05.006_bib5","doi-asserted-by":"crossref","first-page":"6876","DOI":"10.1021\/acs.jmedchem.9b00719","article-title":"3-[(1S,2S,3R)-2,3-Difluoro-1-hydroxy-7-methylsulfonylindan-4-yl]oxy-5-fluorobenzo nitrile (PT2977), a hypoxia-inducible factor 2alpha (HIF-2alpha) inhibitor for the treatment of clear cell renal cell carcinoma","volume":"62","author":"Xu","year":"2019","journal-title":"J\u00a0Med Chem"},{"issue":"5","key":"10.1016\/j.hoc.2023.05.006_bib6","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/s41591-021-01324-7","article-title":"Inhibition of hypoxia-inducible factor-2alpha in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis","volume":"27","author":"Choueiri","year":"2021","journal-title":"Nat Med"},{"issue":"22","key":"10.1016\/j.hoc.2023.05.006_bib7","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1056\/NEJMoa2103425","article-title":"Belzutifan for renal cell carcinoma in von Hippel-Lindau disease","volume":"385","author":"Jonasch","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2023.05.006_bib8","doi-asserted-by":"crossref","first-page":"103750","DOI":"10.1016\/j.critrevonc.2022.103750","article-title":"Targeting hypoxia-inducible factor pathways in sporadic and Von Hippel-Lindau syndrome-related kidney cancers","volume":"176","author":"Iacovelli","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"issue":"18","key":"10.1016\/j.hoc.2023.05.006_bib9","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1016\/j.ejca.2006.09.015","article-title":"The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review","volume":"42","author":"Eskens","year":"2006","journal-title":"Eur J Cancer"},{"issue":"16_suppl","key":"10.1016\/j.hoc.2023.05.006_bib10","doi-asserted-by":"crossref","first-page":"e16533","DOI":"10.1200\/JCO.2022.40.16_suppl.e16533","article-title":"Toxicities of anti-VEGF therapies used in metastatic renal cell carcinoma: a real-world experience","volume":"40","author":"Master","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2023.05.006_bib11","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s11912-012-0242-z","article-title":"VEGF inhibition, hypertension, and renal toxicity","volume":"14","author":"Hayman","year":"2012","journal-title":"Curr Oncol Rep"},{"issue":"9","key":"10.1016\/j.hoc.2023.05.006_bib12","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1200\/JCO.2005.04.5740","article-title":"Angiogenesis inhibitors and hypertension: an emerging","volume":"24","author":"Sica","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2023.05.006_bib13","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1093\/annonc\/mdn713","article-title":"Management of hypertension in angiogenesis inhibitor-treated patients","volume":"20","author":"Izzedine","year":"2009","journal-title":"Ann Oncol"},{"issue":"41","key":"10.1016\/j.hoc.2023.05.006_bib14","doi-asserted-by":"crossref","first-page":"67661","DOI":"10.18632\/oncotarget.11813","article-title":"Incidence and risk of hypertension associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a comprehensive network meta-analysis of 72 randomized controlled trials involving 30013 patients","volume":"7","author":"Liu","year":"2016","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.hoc.2023.05.006_bib15","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/02841860802314720","article-title":"Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis","volume":"48","author":"Zhu","year":"2009","journal-title":"Acta Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2023.05.006_bib16","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1470-2045(08)70003-2","article-title":"Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis","volume":"9","author":"Wu","year":"2008","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2023.05.006_bib17","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s00280-012-2025-5","article-title":"Incidence and risk of hypertension with pazopanib in patients with cancer: a meta-analysis","volume":"71","author":"Qi","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"issue":"9807","key":"10.1016\/j.hoc.2023.05.006_bib18","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/S0140-6736(11)61613-9","article-title":"Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial","volume":"378","author":"Rini","year":"2011","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.hoc.2023.05.006_bib19","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1093\/jnci\/djq091","article-title":"Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors","volume":"102","author":"Maitland","year":"2010","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.hoc.2023.05.006_bib20","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ctrv.2016.12.002","article-title":"Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: a systematic review and meta-analysis","volume":"53","author":"Abdel-Qadir","year":"2017","journal-title":"Cancer Treat Rev"},{"issue":"5","key":"10.1016\/j.hoc.2023.05.006_bib21","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1177\/2047487318755193","article-title":"Cardiovascular diseases in patients receiving small molecules with anti-vascular endothelial growth factor activity: A meta-analysis of approximately 29,000 cancer patients","volume":"25","author":"Totzeck","year":"2018","journal-title":"Eur J Prev Cardiol"},{"issue":"2","key":"10.1016\/j.hoc.2023.05.006_bib22","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.ejca.2009.11.001","article-title":"VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management","volume":"46","author":"Izzedine","year":"2010","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.hoc.2023.05.006_bib23","doi-asserted-by":"crossref","first-page":"102333","DOI":"10.1016\/j.ctrv.2021.102333","article-title":"Management of adverse events associated with cabozantinib plus nivolumab in renal cell carcinoma: a review","volume":"103","author":"McGregor","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.hoc.2023.05.006_bib24","unstructured":"Exelixis, Inc. Cabometyx (cabozantinib) package insert. U.S. Food and Drug Administration. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/208692s010lbl.pdf. Revised Janurary 2021. Accessed April 30, 2023."},{"issue":"10","key":"10.1016\/j.hoc.2023.05.006_bib25","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1093\/annonc\/mdv244","article-title":"Regorafenib-associated hand-foot skin reaction: practical advice on diagnosis, prevention, and management","volume":"26","author":"McLellan","year":"2015","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.hoc.2023.05.006_bib26","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1634\/theoncologist.2008-0131","article-title":"Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib","volume":"13","author":"Lacouture","year":"2008","journal-title":"Oncol"},{"issue":"15","key":"10.1016\/j.hoc.2023.05.006_bib27","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/S1470-2045(15)00290-9","article-title":"Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial","volume":"16","author":"Motzer","year":"2015","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2023.05.006_bib28","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.trre.2014.03.002","article-title":"Strategies for the management of adverse events associated with mTOR inhibitors","volume":"28","author":"Kaplan","year":"2014","journal-title":"Transplant Rev"},{"issue":"3","key":"10.1016\/j.hoc.2023.05.006_bib29","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1164\/rccm.200911-1720OC","article-title":"Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma","volume":"182","author":"White","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"10.1016\/j.hoc.2023.05.006_bib30","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1093\/annonc\/mdw141","article-title":"Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies","volume":"27","author":"Naidoo","year":"2016","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2023.05.006_bib31","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.jaad.2020.03.132","article-title":"Immune checkpoint inhibitor-related dermatologic adverse events","volume":"83","author":"Geisler","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"12","key":"10.1016\/j.hoc.2023.05.006_bib32","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"issue":"36","key":"10.1016\/j.hoc.2023.05.006_bib33","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2023.05.006_bib34","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1200\/OP.21.00776","article-title":"Management of the Top 10 most common immune-related adverse events in patients treated with immune checkpoint inhibitor therapy","volume":"18","author":"Schneider","year":"2022","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.hoc.2023.05.006_bib35","unstructured":"Available at: https:\/\/www.sitcancer.org\/research\/cancer-immunotherapy-guidelines. Society for Immunotherapy of Cancer (SITC) Cancer Immunotherapy Guidelines.(Accessed on January 10, 2022)."},{"issue":"2","key":"10.1016\/j.hoc.2023.05.006_bib36","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis","volume":"4","author":"Barroso-Sousa","year":"2018","journal-title":"JAMA Oncol"},{"issue":"14","key":"10.1016\/j.hoc.2023.05.006_bib37","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.hoc.2023.05.006_bib38","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/S1470-2045(19)30413-9","article-title":"Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial","volume":"20","author":"Motzer","year":"2019","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2023.05.006_bib39","doi-asserted-by":"crossref","first-page":"e001079","DOI":"10.1136\/esmoopen-2020-001079","article-title":"Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial","volume":"5","author":"Albiges","year":"2020","journal-title":"ESMO Open"},{"issue":"12","key":"10.1016\/j.hoc.2023.05.006_bib40","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.hoc.2023.05.006_bib41","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Motzer","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.hoc.2023.05.006_bib42","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S1470-2045(20)30436-8","article-title":"Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial","volume":"21","author":"Powles","year":"2020","journal-title":"Lancet Oncol"},{"issue":"14","key":"10.1016\/j.hoc.2023.05.006_bib43","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.hoc.2023.05.006_bib44","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1038\/s41591-020-1044-8","article-title":"Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial","volume":"26","author":"Motzer","year":"2020","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.hoc.2023.05.006_bib45","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.annonc.2020.04.010","article-title":"Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma","volume":"31","author":"Choueiri","year":"2020","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.hoc.2023.05.006_bib46","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"15_suppl","key":"10.1016\/j.hoc.2023.05.006_bib47","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1200\/JCO.2021.39.15_suppl.4500","article-title":"Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from 42-month follow-up of KEYNOTE-426","volume":"39","author":"Rini","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"6_suppl","key":"10.1016\/j.hoc.2023.05.006_bib48","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1200\/JCO.2021.39.6_suppl.308","article-title":"Nivolumab\u00a0+ cabozantinib (NIVO+CABO) versus sunitinib (SUN) for advanced renal cell carcinoma (aRCC): Outcomes by sarcomatoid histology and updated trial results with extended follow-up of CheckMate 9ER","volume":"39","author":"Motzer","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.hoc.2023.05.006_bib49","doi-asserted-by":"crossref","first-page":"4553","DOI":"10.1200\/JCO.2021.39.15_suppl.4553","article-title":"Nivolumab plus cabozantinib (N+C) versus sunitinib (S) for advanced renal cell carcinoma (aRCC): Outcomes by baseline disease characteristics in the phase 3 CheckMate 9ER trial","volume":"39","author":"Apolo","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl_5","key":"10.1016\/j.hoc.2023.05.006_bib50","first-page":"S678","article-title":"Phase III CLEAR trial in advanced renal cell carcinoma (aRCC): Outcomes in subgroups and toxicity update","volume":"32","author":"Choueiri","year":"2021","journal-title":"Ann Oncol"},{"issue":"31","key":"10.1016\/j.hoc.2023.05.006_bib51","doi-asserted-by":"crossref","first-page":"3672","DOI":"10.1200\/JCO.20.01652","article-title":"Phase I study of cabozantinib and nivolumab alone or with ipilimumab for advanced or metastatic urothelial carcinoma and other genitourinary tumors","volume":"38","author":"Apolo","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2023.05.006_bib52","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1172\/JCI133194","article-title":"Marked and rapid effects of pharmacological HIF-2alpha antagonism on hypoxic ventilatory control","volume":"130","author":"Cheng","year":"2020","journal-title":"J\u00a0Clin Invest"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858823000618?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858823000618?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:21:10Z","timestamp":1760185270000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858823000618"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":52,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S0889858823000618"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2023.05.006","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Toxicity Management of Systemic Kidney Cancer Therapies","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2023.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}